Korean J Urol.  1992 Aug;33(4):575-582.

Cell proliferation of transitional cell carcinoma of the bladder measured bu monoclonal antibody Ki-67

Affiliations
  • 1Department of Urology, Seoul National University, College of Medicine, Seoul, Korea.

Abstract

The cell proliferation of 29 human transitional cell carcinomas of the bladder was assessed immunohistochemically using the monoclonal antibody Ki-67. Normal mucosa had a mean value of 0.67+/-0.20% cells positive for Ki-67, whereas the average of grade 1. 2, 3 was 5.2+/-1.8%. 12.2: 5.0%, 18.0+/-4.6%. respectively. Significant differences were noted between grade 1 and grade 2 (p intermediate Nde (grade 2) showed wide range of Ki-67 labeling index (from 6.5 to 23.5%) compared with ether grades. The labeling indices of Ki-67 were 5.5+/-2.1% for stage Ta. 11.9+/-4.2% for T1 and 17.4+/-5.8% for stages equal to or higher than T2. Significant difference was noted between stage Ta and T1 (p<0.001 ), suggesting that tumor invasion to lamina propria is a important indicator of cell proliferation. Significant difference was also noted between stage T1 and T2 or higher (p<0.01). In recurrent tumors, Ki-67 indices did not show significant difference between the tumors with short recurrent intervals(men duration of recurrence <6 months) and long(>6 months). In conclusion. we suggest that Ki-67 may be a useful monoclonal antibody for easy evaluation of proliferating cells in transitional cell carcinomas of the bladder and Ki-67 labeling indices may serves as a additional prognostic factor to the current histologic grade of the bladder tumor, especially in the tumors with the intermediate grade.

Keyword

cell proliferation; transitional cell carcinoma

MeSH Terms

Carcinoma, Transitional Cell*
Cell Proliferation*
Ether
Humans
Mucous Membrane
Recurrence
Urinary Bladder Neoplasms
Urinary Bladder*
Ether
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr